Introduction {#s1}
============

Infertility was reported affecting 10--15% of couples, and roughly half of which are due to the man's problem [@pone.0053443-Okabe1], [@pone.0053443-Dohle1]. Spermatogenic impairment is the most common form of male infertility, which is closely related with impaired preimplantation development, low fertilization rate, increased abortion and elevated incidence of disease in the offspring, and as well as child cancer [@pone.0053443-Brinkworth1]. Spermatogenesis is a highly regulated process which can be subdivided into three main phases: mitotic proliferation, meiosis and sperm morphogenesis, among which, the meiosis is an important event in the process of sexual reproduction of biology gametes (including male gametes and female gametes) generation, and its smooth start is key to the final completion of meiosis. But we still lack a detailed understanding of the molecular mechanism for the initiation of germ cell meiosis [@pone.0053443-Pawlowski1], [@pone.0053443-BolcunFilas1], [@pone.0053443-Ohta1], [@pone.0053443-Kocer1]. Recently, a series of studies have shown that several genes (*CYP26B1*, *NANOS1*, *STRA8 et al*) co-modify the process of meiotic program initiation [@pone.0053443-BolcunFilas1], [@pone.0053443-Ohta1], [@pone.0053443-Anderson1], [@pone.0053443-Koubova1].

Of these genes, the *STRA8*, stimulated by retinoic acid gene 8, was activated by retinoic acid (RA), which can directly enter the nucleus and bind to the corresponding retinoic acid receptor (RAR) to regulate the expression of specific genes. RA plays an important role in the process of cell growth, differentiation and apoptosis, and is catabolized by a family of cytochrome P450 (CYP) enzymes, *CYP26A1*, *CYP26B1* and *CYP26C1* [@pone.0053443-Tahayato1], [@pone.0053443-White1], [@pone.0053443-White2]. *CYP26B1* is expressed in not the embryonic ovary but the embryonic testis, implying that the *CYP26B1* is closely associated with male germ cell development. The expression of *CYP26B1* in the testis of wild-type mouse is increased at embryonic day (E) 11.5, prior to mitotic arrest, and then reduced at E13.5 [@pone.0053443-Bowles1]. The degradation effect of *CYP26B1* on *RA* concentration may inactivate *STRA8*, thus ensuring the normal development of spermatogonia. Previous study reports that genetic deletion of *CYP26B1* leads to increased *RA* levels and activation of *STRA8* in the embryonic testes. As a consequence, male germ cells are prematurely entering into meiosis, arrested at pachytene stage, causing a rapid increase in apoptosis and a lack of spermatogonia of male mice after birth [@pone.0053443-Bowles1], [@pone.0053443-MacLean1], [@pone.0053443-Ross1], [@pone.0053443-Trautmann1]. If no other *STRA8* inhibitory factors exist, the concentration of RA will be increased, and the *STRA8* will be re-activated. To ensure the process of meiosis initiation go normally, other inhibitory factors are required.

The *NANOS* (human *NANOS1*, mice *Nanos2* and *Nanos3*) is one of the evolutionarily conserved proteins implicated in germ cell development and closely related with somite and germ cell development [@pone.0053443-Saga1]. It was reported the phenotype of *Nanos2* knockout mice's testis during the embryonic period was similar to that of *Cyp26b1* functional defects [@pone.0053443-Tsuda1]. It was interesting that *Stra8* expression in these two gene knockout mice showed certain period difference. In the testis of *Cyp26b1* knockout mice, it begins to express highly in embryonic E13.5, but appears at E14.5 and continues until after birth in Nanos2 knockout mice's testis. It seems that the *Nanos2* begins to play an inhibitory effect on *Stra8* when the *Cyp26b1* expression decreases [@pone.0053443-Ohta1], [@pone.0053443-Tsuda1]. The synergy of these three regulating factors avoids the early meiosis initiation of spermatogonial cells, which ensures the normal development of sperm [@pone.0053443-Suzuki1]. Thus, *STRA8*, *CYP26B1, and NANOS1* were chosen as the typical meiotic program initiation pathway genes in this study.

Considering the essential role of meiotic program initiation pathway genes in spermatogenesis, we speculate that genetic variants of these genes have the potential to affect normal spermatogenesis. To test our hypothesis, we performed genotyping analyses for eight SNPs (rs2241057, rs707718, rs1422627, rs9304651, rs2015728, rs10269148, rs17168319 and rs17168337) in these genes, and investigated the association between these genetic variants and idiopathic infertility in a Chinese population. To the best of our knowledge, this is the first time to investigate the associations between these meiotic program initiation pathway gene polymorphisms and susceptibility to spermatogenic impairment.

Materials and Methods {#s2}
=====================

Subject Recruitment and Sample Collection {#s2a}
-----------------------------------------

The study was approved by the Ethics review board of Nanjing medical university. The protocol and consent form were approved by the Institutional Review Board of Nanjing Medical University prior to the study. All participants provided their written informed consent to join in this study. And all the subjects were genetically unrelated ethnic Han-Chinese from East China. Every participant received complete medical history questionnaire, physical examinations and semen analysis. All infertility patients were examined, among which, those with a history of Y chromosome microdeletions, cytogenetic abnormalities, congenital bilateral absence of vas deferens, cryptorchidism and orchitis were excluded [@pone.0053443-Li1]. Additionally, subjects having special occupational exposure which may be suspected to affect semen quality were precluded. After completing the questionnaire, each subject donated 5 ml of blood used for genomic DNA extraction.

SNP Selection and Genotype Analyses {#s2b}
-----------------------------------

Through information gained from PubMed and Hapmap searches, we identified the potential functional polymorphisms in *CYP26B1, NANOS1* and *STRA8.* All selected single nucleotide polymorphisms (SNPs) have reported minor allele frequencies (MAF) of \>0.05 in Pubmed and are located in exons and UTRs. In the case of multiple SNPs in the same haplotype block (linkage coefficient r^2^\>0.8), only one was selected`. `Finally, we identified eight potential functional polymorphisms (rs2241057, rs707718, rs1422627, rs9304651, rs2015728, rs10269148, rs17168319 and rs17168337) in three genes involved in the meiotic program initiation ([Table 1](#pone-0053443-t001){ref-type="table"}).

10.1371/journal.pone.0053443.t001

###### The meiotic program initiation pathway genes and polymorphisms evaluated in this study.

![](pone.0053443.t001){#pone-0053443-t001-1}

  Gene         SNP ID      Position     Nucleotide change   Amino acid change   MAF (℅)[a](#nt102){ref-type="table-fn"}   p value for HWE Test
  --------- ------------ ------------- ------------------- ------------------- ----------------------------------------- ----------------------
  Cyp26b1    rs2241057       nsSNP            T\>C              Leu\>Ser                         11.0                            0.552
              rs707718       3′UTR            A\>C                 --                            45.3                            0.878
  Nanos2     rs1422627       3′UTR            T\>C                 --                            30.2                            \<0.01
             rs9304651    5′near gene         A\>G                 --                             9.8                            0.472
             rs2015728    5′near gene         G\>T                 --                            27.4                            0.449
  Stra8      rs10269148   5′near gene         C\>G                 --                             3.5                            0.735
             rs17168319   5′near gene         A\>G                 --                            23.2                            0.931
             rs17168337   3′near gene         C\>G                 --                            31.1                            0.386

Abbreviations: nsSNP, non-synonymous; UTR, untranslated region; MAF, minor allele frequency; HWE, Hardy-Weinberg equilibrium.

Minimum allele frequency in the general Han Chinese population, as reported in dbSNP database.

Genomic DNA of the subjects was isolated from peripheral blood lymphocytes. These SNPs were genotyped by using TaqMan SNP allelic discrimination. For quality control, 10% of the samples were randomly genotyped again, and the reproducibility was 100%.

Statictical Analysis {#s2c}
--------------------

Statistical analyses were carried out using the Stata 10.0 statistical package (StataCorp LP, USA). The Hardy-Weinberg equilibrium (HWE) tests were performed on online software, SHEsis (<http://analysis.bio-x.cn/myAnalysis.php>). The subjects with idiopathic infertility were first divided into two groups according to semen parameters: the abnormospermia group with sperm count below the WHO reference value and the normozoospermia group with the normal sperm count at or above the WHO reference value. And then the abnormospermia group was further divided into two subgroups: the azoospermia group and the oligozoospermia group. The semen analysis was described previously [@pone.0053443-Li1]. Values for semen parameters were the mean of at least two analyses.

Analysis of variance (ANOVA) was used to compare the mean age, tea consumption, Body Mass Index (BMI) between the case and control groups. The chi-squared test was used to evaluate the differences in smoking status and drinking status of each SNP in the three genes between the case and control groups. Estimated infertility risks with odds ratios (OR) and 95% confidence intervals (95%CI) were calculated by multivariate logistic regression with adjustment for age, smoking status and BMI, where it was appropriate. Two-sided tests were used and the Bonferroni adjustment for multiple testing was applied. The applied *p*-value for a truly significant result is calculated as 0.05/n.

Results {#s3}
=======

Characteristics of the Study Populations {#s3a}
----------------------------------------

The final population consisted of 1102 Han Chinese subjects, composed of 383 fertile controls, 201 azoospermia, 155 oligozoospermia and 363 infertility/normozoospermia. The distributions of selected characteristics among the case and control subjects were presented in [Table 2](#pone-0053443-t002){ref-type="table"}. All groups had similar patterns of drinking and tea consumption (*p*\>0.05). The mean ages were higher in the groups of all infertility, azoospermia and oligozoospermia than the control group (all *p*\<0.05). BMI levels in the group of all infertility were significantly higher than those in the control subjects. Smoking prevalence was higher in the azoospermia group than the control group (*p*\<0.05).

10.1371/journal.pone.0053443.t002

###### The distributions of selected variables among cases and control subjects.

![](pone.0053443.t002){#pone-0053443-t002-2}

  Variables                                        Fertility/normozoospermia(n = 383)   Infertility/abnormospermia (n = 356)   Azoospermia (n = 201)            Oligozoospermia (n = 155)               Infertility/normozoospermia(n = 363)                All infertility(n = 719)            
  ----------------------------------------------- ------------------------------------ -------------------------------------- ----------------------- --------------------------------------------- --------------------------------------------- --------------------------------------------- ------------
  [a](#nt103){ref-type="table-fn"}Age, mean(SD)                29.79±3.55                            29.22±4.50                     29.55±4.78         28.79±4.08[\*](#nt105){ref-type="table-fn"}   29.17±4.20[\*](#nt105){ref-type="table-fn"}   29.19±4.35[\*](#nt105){ref-type="table-fn"}  
  [b](#nt104){ref-type="table-fn"}Smoking                         Ever                               218(56.92)                     184(51.69)         97(48.26) [\*](#nt105){ref-type="table-fn"}                    87(56.13)                                    193(53.17)                    377(52.43)
                                                                 Never                               165(43.08)                     172(48.31)                         104(51.74)                                     68(43.87)                                    170(46.83)                    342(47.57)
  [b](#nt104){ref-type="table-fn"}Drinking                        Ever                               214(55.87)                     198(55.62)                         114(56.72)                                     84(54.19)                                    179(49.31)                    377(52.43)
                                                                 Never                               169(44.13)                     158(44.38)                          87(43.28)                                     71(45.81)                                    184(50.69)                    342(47.57)
  Tea consumption                                                 Ever                               212(55.35)                     176(49.44)                         103(51.24)                                     73(47.10)                                    200(55.10)                    376(52.29)
                                                                 Never                               171(44.65)                     180(50.56)                          98(48.76)                                     82(52.90)                                    163(44.90)                    343(47.71)
  [a](#nt103){ref-type="table-fn"}BMI, mean(SD)                23.62±2.92                            23.21±3.02                     23.15±2.91                         23.28±3.17                                    23.20±3.02                    23.21±3.02[\*](#nt105){ref-type="table-fn"}  

Independent-samples T-test for comparing the mean of the age, BMI and Pack-years of smoking between the cases and controls.

Two-sided chi-squared test for either selected variable distributions between cases and controls.

p\<0.05 for two-sided chi-squared test for either selected characteristics distributions or allele frequencies between control and case group.

Associations between Polymorphisms and Spermatogenic Impairment {#s3b}
---------------------------------------------------------------

The position and minor allele frequency of the 8 potential functional SNPs, were presented in [Table 1](#pone-0053443-t001){ref-type="table"}. All SNPs frequencies were in accordance with HWE, except rs1422627 which had a *p* value \<0.01 for deviation from HWE. The associations between meiosis initiation genes SNPs and the risks of male infertility were shown in [Table 3](#pone-0053443-t003){ref-type="table"}. According to the [Table 2](#pone-0053443-t002){ref-type="table"}, 95% CI was adjusted for the age, BMI and smoking in cases and controls because of its significant distribution differences.

10.1371/journal.pone.0053443.t003

###### Associations of selected meiotic program initiation pathway gene polymorphisms and the risk of idiopathic male infertility.

![](pone.0053443.t003){#pone-0053443-t003-3}

                Genotype   Control^af^   Infertility[b](#nt108){ref-type="table-fn"}/abnormospermia   Azoospermia[c](#nt109){ref-type="table-fn"}   Oligozoospermia[d](#nt110){ref-type="table-fn"}   Infertility[e](#nt111){ref-type="table-fn"}/normozoospermia   All infertility                                                                                                      
  ------------ ---------- ------------- ------------------------------------------------------------ --------------------------------------------- ------------------------------------------------- ------------------------------------------------------------- ------------------ ------- ----- ------------------ ------- ----- ------------------ ------- ----- ------------------ -------
  CYP26B1                                                                                                                                                                                                                                                                                                                                                                                
  rs2241057        TT          318                                  308                                                  1.00                                            0.401                                                    169                                     1.00         0.949   139         1.00         0.129   321         1.00         0.099   629         1.00         0.116
                   CT          63                                    46                                            0.75(0.50--1.14)                                                                                               31                                0.96(0.60--1.53)           15    0.53(0.29--0.96)           40    0.61(0.40--0.94)           86    0.68(0.48--0.97)  
                 CT/CC         65                                    48                                            0.76(0.51--1.14)                                      0.188                                                    32                                0.96(0.60--1.53)   0.746   16    0.54(0.30--0.98)   0.051   42    0.62(0.41--0.94)   0.035   90    0.68(0.48--0.97)   0.043
  rs707718         AA          97                                   111                                                  1.00                                            0.206                                                    55                                      1.00         0.740   56          1.00         0.039   99          1.00         0.824   210         1.00         0.392
                   AC          190                                  161                                            0.74(0.52--1.04)                                                                                               93                                0.88(0.58--1.33)           68    0.61(0.40--0.95)           177   0.91(0.64--1.29)           338   0.81(0.60--1.09)  
                 AC/CC         286                                  245                                            0.75(0.54--1.03)                                      0.077                                                    146                               0.92(0.62--1.36)   0.594   99    0.59(0.40--0.89)   0.012   264   0.90(0.65--1.25)   0.546   509   0.81(0.61--1.08)   0.171
  NANOS1                                                                                                                                                                                                                                                                                                                                                                                 
  rs9304651        AA          330                                  297                                                  1.00                                            0.579                                                    164                                     1.00         0.347   133         1.00         0.975   306         1.00         0.741   603         1.00         0.600
                   AG          50                                    56                                            1.24(0.82--1.88)                                                                                               35                                1.38(0.86--2.21)           21    1.08(0.62--1.87)           53    1.20(0.79--1.83)           109   1.21(0.84--1.74)  
                 AG/GG         53                                    59                                            1.24(0.83--1.85)                                      0.300                                                    37                                1.38(0.87--2.19)   0.146   22    1.07(0.62--1.83)   0.914   57    1.22(0.81--1.84)   0.473   116   1.21(0.85--1.73)   0.314
  rs2015728        GG          207                                  191                                                  1.00                                            0.282                                                    112                                     1.00         0.530   79          1.00         0.215   206         1.00         0.117   397         1.00         0.127
                   GT          153                                  133                                            0.94(0.69--1.28)                                                                                               73                                0.88(0.61--1.26)           60    1.04(0.70--1.55)           124   0.83(0.61--1.12)           257   0.91(0.70--1.18)  
                 GT/TT         176                                  165                                            1.02(0.76--1.36)                                      0.914                                                    89                                0.93(0.66--1.31)   0.699   76    1.15(0.79--1.67)   0.517   157   0.91(0.68--1.21)   0.458   322   0.98(0.76--1.26)   0.711
  STRA8                                                                                                                                                                                                                                                                                                                                                                                  
  rs10269148       CC          370                                  332                                                  1.00                                            0.006                                                    184                                     1.00         0.002   148         1.00         0.124   344         1.00         0.066   667         1.00         0.010
                   CG          13                                    29                                            2.52(1.29--4.94)                                                                                               19                                2.92(1.41--6.06)           10    1.89(0.81--4.44)           23    1.86(0.93--3.74)           52    2.22(1.19--4.14)  
                 CG/GG         13                                    29                                            2.52(1.29--4.94)                                      0.006                                                    19                                2.92(1.41--6.06)   0.002   10    1.89(0.81--4.44)   0.124   23    1.86(0.93--3.74)   0.066   52    2.22(1.19--4.14)   0.010
  rs17168319       AA          217                                  188                                                  1.00                                            0.500                                                    104                                     1.00         0.440   84          1.00         0.847   210         1.00         0.701   398         1.00         0.908
                   AG          143                                  148                                            1.19(0.88--1.62)                                                                                               86                                1.28(0.90--1.83)           62    1.13(0.76--1.68)           127   0.92(0.68--1.25)           275   1.04(0.80--1.35)  
                 AG/GG         166                                  168                                            1.17(0.87--1.56)                                      0.293                                                    97                                1.25(0.89--1.76)   0.257   71    1.10(0.76--1.61)   0.602   153   0.95(0.71--1.28)   0.742   321   1.04(0.81--1.34)   0.678
  rs17168337       CC          160                                  165                                                  1.00                                            0.440                                                    91                                      1.00         0.620   74          1.00         0.247   164         1.00         0.643   329         1.00         0.439
                   CG          181                                  153                                            0.82(0.60--1.11)                                                                                               92                                0.91(0.63--1.31)           61    0.72(0.48--1.08)           161   0.86(0.63--1.17)           314   0.83(0.64--1.08)  
                 CG/GG         223                                  191                                            0.83(0.62--1.11)                                      0.211                                                    110                               0.89(0.63--1.26)   0.417   81    0.78(0.53--1.14)   0.206   199   0.86(0.65--1.16)   0.349   390   0.84(0.65--1.08)   0.205

SNPs, single-nucleotide polymorphisms; OR, odds ratios; CI, confidence interval.

Subjects consisted of proven fertility men with semen volume ≥2 ml, sperm counts ≥20×10^6^/ml and sperm motility ≥50% motile sperm.

Subjects consisted of idiopathic infertile men with sperm counts \<20×10^6^/ml.

Subjects consisted of idiopathic infertile men with sperm counts = 0/ml.

Subjects consisted of idiopathic infertile men with sperm counts from 0.1 to 20×10^6^/ml.

Subjects consisted of idiopathic infertile men with sperm counts ≥20×10^6^/ml.

ORs were obtained from multivariate logistic regression analysis.

Two-sided χ2 test for genotype distributions between cases and controls.

Initially, we overviewed the frequency distribution between the total case group and the control group, and no significant difference was found. To investigate the possible role of the meiotic program initiation pathway genes in spermatogenesis, we subdivided the case group into two subgroups on the basis of sperm concentration: infertility/abnormospermia and infertility/normozoospermia. The genotype frequencies of rs10269148 in *STRA8* were significantly different existed between the infertility/abnormospermia group and the control group. Then the subgroup of infertility/abnormospermia was further stratified into two subgroups: the azoospermia group and the oligozoospermia group. Compared to the control group, statistically significant increased risk of idiopathic spermatogenic impairment was found for carriers of rs10269148CG genotype of *STRA8*, when compared with homozygous carriers of the C allele in the infertility/abnormospermia group and azoospermia subgroup respectively \[ORs and 95% CIs being 2.52 (1.29--4.94), 2.92 (1.41--6.06)\], while in the oligozoospermia group, the frequency distribution showed no significant difference. These results suggested that the G allele of rs10269148(C\>G) may contribute to the severe idiopathic spermatogenic impairment.

To the rs2241057 of *CYP26B1*, although the distribution frequencies were lower in the total infertility group \[12.52% (CT+CC)\] than that in the control group \[16.98% (CT+CC)\], the distribution difference was not statistically significant after Bonferroni correction (p = 0.04\>0.05/7 OR = 0.68, 95% CI = 0.48--0.97). And to the rs707718, logistic regression analysis revealed that compared with the rs707718 AA genotype, subjects in oligozoospermia group carrying the heterozygous rs707718 AC genotype had a significantly 39% decreased risk of spermatogenic impairment (OR = 0.61, 95% CI = 0.40--0.95). When we combined the rs707718 AC and CC genotype, assuming a co-dominant allele effect, the combined rs707718 AC+CC variant genotypes were associated with a 41% (OR = 0.59, 95% CI = 0.40--0.89) reduced risk of spermatogenic impairment. The OR values suggested that the variants rs2241057T\>C, rs707718A\>C may be protective factors against the risk of idiopathic male infertility with abnormal and/or normal semen parameters.

As to the other SNPs, no significant differences of distribution frequencies were identified among the case and control groups. In our study, due to the low occurrence frequency in Asians, we didn't analyse homozygous mutant separately.

Discussion {#s4}
==========

Although meiosis initiation genes have been recognized as key regulators in sperm function and male fertility [@pone.0053443-MacLean1], [@pone.0053443-Tsuda1], [@pone.0053443-Swain1], there have been few studies concerning the potential role of genetic variants of meiosis initiation genes in infertility, particularly idiopathic male infertility. *STRA8* is required for premeiotic DNA replication, while *CYP26B1* is decreased. By preventing *STRA8'*s expression, *CYP26B1* and *NANOS1* play critical roles in the differentiation of male germ cells [@pone.0053443-Koubova1], [@pone.0053443-Bowles1], [@pone.0053443-MacLean1], [@pone.0053443-Baltus1]. In all, the entry of testicular germ cells into meiotic program may be partly controlled by the stage-specific expression of *CYP26B1*and *NANOS1* expression in the germ cells [@pone.0053443-Koubova1], [@pone.0053443-Bowles1]. To investigate the exact role of meiotic initiation pathway genes, key downstream antagonists (*CYP26B1*, *NANOS1*) and effectors (*STRA8*) of the meiosis-inducing action of *RA* were analyzed in this study. Through information gained from PubMed and Hapmap searches, eight potential functional polymorphisms in meiosis initiation genes were examined.

*Vivo* studies have demonstrated that male mice lacking *STRA8* function produce no sperm [@pone.0053443-Anderson1], [@pone.0053443-Revenkova1] mainly by hampering the homologous-chromosome pairing way [@pone.0053443-Mark1]. But the exact functional genetic variants of this gene remain unclear. In this study, we found the rs10269148 significantly increased the risk of spermatogenic impairment associated with abnormal semen parameters (*p* = 0.006). In the following stratified analysis, compared with homozygous type CC, the rs10269148 C\>G increased the risk of azoospermia and displayed 2.92 fold increased risk of spermatogenic impairment, which was consistent with the phenotypes in STRA8^−/−^ mice [@pone.0053443-Anderson1]. While in male mutant mice, the premeiotic DNA replication was conserved [@pone.0053443-Anderson1] and the germ cells could partly condense chromosomes, and initiate meiotic recombination until the leptotene stage of prophase I [@pone.0053443-Mark1]. SNP rs10269148 is located in 5′-untranslated region of the STRA8 gene, and may affect gene function by altering transcription factor-binding sites, or the location, level and timing of gene expression [@pone.0053443-Anderson1], [@pone.0053443-Mark1]. To clarify the precise mechanism, functional research should be conducted in the future. In fetal testis, the expression of *STRA8* is suppressed by a retinoid-degrading enzyme, which is mainly coded by *CYP26B1*. The *CYP26B1*, an important member of *CYP* family, is expressed in sertoli cells, and has a crucial role in the formation of sperm [@pone.0053443-Koubova1], [@pone.0053443-Ross1], [@pone.0053443-Trautmann1]. We found that individuals carrying rs2241057 genotype in the coding region of *CYP26B1*, which causes Leu to Ser substitution at position 264 (rs2241057 T\>C) (<http://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=2241057>), may lower the risk of spermatogenic impairment in our study population. As to the rs707718, comparing with homozygous type AA, the A\>C mutation significantly reduced the risk of spermatogenic impairment, displaying 0.59 fold decreased risk of spermatogenic impairment (OR = 0.59, 95% CI = 0.40, 0.89, *p* = 0.012). However this difference disappeared after the Bonferroni correction. The statistical power of our study may be limited by the small sample size.

Our results were consistent with that the substitution of *CYP26B1* (rs2241057 T\>C) enhanced the catabolicing activity of *CYP26B1* substantially, both in a cell free system and in cell culture. The actual catabolic rates in *vivo* depend on the local tissue concentration of atRA and many other factors, which cannot be accurately predicted from the data. But it is plausible that the differences between variants of *CYP* enzyme alter the equilibrium of etinoid synthesis and catabolism [@pone.0053443-Ross2], [@pone.0053443-Wolf1]. Considering the function of *CYP26B1* in biogenesis and postnatal growth, we speculate that the genetic variation may affect the capacity of *CYP26B1* enzyme, then the meiotic program of germ cell, which might tightly associates with male infertility.

Although *CYP26B1* has an important inhibitory effect during the early initiation of meiosis in testicular germ cells, when it comes to E13.5, the expression begins to decrease [@pone.0053443-Bowles1], [@pone.0053443-Ross1], which results in subsequent increase of RA concentration, thus producing the possibility of re-activation of *STRA8*. So the other *STRA8* inhibitory factors- *NANOS1* are required before the spermatogonial cells initiating meiosis. Given that *NANOS1* is an RNA-binding protein localized in the cytoplasm, we suspected the regulation of *STRA8* transcription may be an indirect effect of *NANOS1* [@pone.0053443-Suzuki1]. In our study, we did not find any functional genetic variant of this gene. Thus, we speculated that the effect of the *NANOS1* gene on the *STRA8* gene might be moderate and other macromolecules might participate in the initiation of meiosis. The precise mechanism of the variants of *NANOS1* in male infertility needs further investigation.

In conclusion, the results of our study demonstrated for the first time that some representative genetic variants in the meiosis initiation genes might regulate the risk of male infertility. Although the statistical power of our study was limited by the small sample size in the subgroups, our findings might be helpful to understand the mechanism of male infertility. Larger sample size studies and in vivo or in vitro functional studies will be needed to substantiate the biological roles of these variants.
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